BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 5, 2018
View Archived Issues
SRC-3 shushes stem cells
Read More
Misfolded tau proteins differ by tauopathy
Read More
Novartis describes profile of promising BTK inhibitor LOU-064
Read More
BAY-1101042, a potent NO- and heme-independent sGC activator suitable for oral dosing
Read More
Selective nonlethal mechanism-based inhibitors of gut microbial TMAO reduce thrombosis potential
Read More
Medications for alcohol or opioid use disorders may reduce suicidal behavior and criminality
Read More
New phase I trial evaluates Inovio's GLS-6150 to prevent hepatitis C
Read More
OPKO Health announces initiation of phase II study of Rayaldee in dialysis patients
Read More
Additional positive data presented from phase IIa study of NasoVAX intranasal influenza vaccine
Read More
Boehringer Ingelheim and Tsinghua University to develop novel therapies against infectious diseases
Read More
Nerlynx approved in Europe as extended adjuvant therapy of HER2-positive early-stage breast cancer
Read More
Positive results reported across multiple endpoints in ZENITH-1 trial of oral BCX-7353
Read More
Ossianix to use BBB delivery technology with agents from Novo Nordisk
Read More
Development of a new PDE9A inhibitor for the treatment of CNS diseases
Read More
National Institute of Pharmaceutical R&D divulges BTK ihibitors
Read More
Palobiofarma and Novartis patent adenosine A2A receptor antagonists
Read More
FDA grants IND clearance for phase II/III study of LYS-SAF-302 for MPS IIIA
Read More
Galderma Research & Development discloses RORC inverse agonists
Read More
Oryzon Genomics identifies new lysine-specific demethylase inhibitors
Read More
Tesaro advances JASPER study of Zejula in NSCLC
Read More
Turnstone Biologics and La Jolla Institute collaborate to develop new cancer immunotherapies
Read More
Elunate approved in China for colorectal cancer
Read More
Pieris initiates phase I trial of PRS-343 plus atezolizumab in HER2-positive solid tumors
Read More
New PARP-1 inhibitor presented for cancer
Read More